Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-7262 alone and with enlicitide in adults with elevated lipoprotein(a)
2025-525102-38-00Phase 2Authorised
- Sponsor
- Merck & Co.
- Start
- Aug 2026
- Modality
- Small Molecules, Cyclic Peptides → Modified Peptides → Peptides
- Countries
- 9
01
Overview
Phase 2, randomised, double-blind trial of gefapixant and enlicitide in lipoprotein(a) hyperlipoproteinemia (Lp(a)) and hyperlipidemia (4 arms), sponsored by Merck & Co. Primary endpoints: Percent Change from Baseline in Lipoprotein(a) at Week 8, Percent Change from Baseline in LDL-C at Week 8 and 2 more. Planned start Aug 2026; status: authorised.
02
Drugs
gefapixantenlicitide
03
Conditions
lipoprotein(a) hyperlipoproteinemia (Lp(a))hyperlipidemia
Beyond the preview
Go deeper on 2025-525102-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-525102-38-00.